This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
WILMINGTON, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- DUSA Pharmaceuticals, Inc.
® (Nasdaq:DUSA), a dermatology company that is developing and marketing Levulan
® Photodynamic Therapy (PDT), announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 14
th Annual Healthcare Conference on Monday, September 10, 2012 at 11:15 a.m. ET at The Waldorf Astoria Hotel in New York City.
Interested parties can click
here to access a live webcast of the presentation or visit our website at
www.dusapharma.com . An archived version of the presentation will be available on the DUSA website for 90 days following the presentation.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan
® PDT technology platform. Levulan
® (aminolevulinic acid HCl) for Topical Solution, 20% plus blue light illumination using DUSA's BLU-U
® Blue Light Photodynamic Therapy Illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. DUSA is based in Wilmington, Mass. Please visit our website at
CONTACT: Chad Rubin
Investor Relations Contact
The Trout Group LLC